Currently, PI3Kα inhibitors, including inavolisib and alpelisib, have demonstrated the capacity to induce durable disease control in patients with PIK3CA‐mutated breast cancer [229, 230, 231]. This evidence concerns the gene PIK3CA and breast cancer.